Finch Therapeutics Group (FNCH) Competitors $12.50 0.00 (0.00%) As of 01:37 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. FBRX, ENTX, TCRX, IGMS, VRCA, CABA, EPIX, ZURA, IPA, and QNCXShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Forte Biosciences (FBRX), Entera Bio (ENTX), TScan Therapeutics (TCRX), IGM Biosciences (IGMS), Verrica Pharmaceuticals (VRCA), Cabaletta Bio (CABA), ESSA Pharma (EPIX), Zura Bio (ZURA), ImmunoPrecise Antibodies (IPA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Forte Biosciences Entera Bio TScan Therapeutics IGM Biosciences Verrica Pharmaceuticals Cabaletta Bio ESSA Pharma Zura Bio ImmunoPrecise Antibodies Quince Therapeutics Forte Biosciences (NASDAQ:FBRX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do analysts prefer FBRX or FNCH? Forte Biosciences presently has a consensus target price of $61.00, indicating a potential upside of 499.21%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, FBRX or FNCH? Forte Biosciences has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Which has stronger valuation & earnings, FBRX or FNCH? Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.62Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.42 Do insiders & institutionals have more ownership in FBRX or FNCH? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to FBRX or FNCH? In the previous week, Finch Therapeutics Group had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.29 beat Finch Therapeutics Group's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media. Company Overall Sentiment Forte Biosciences Positive Finch Therapeutics Group Neutral Is FBRX or FNCH more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -149.15% -114.25% Finch Therapeutics Group N/A -69.14%-26.92% SummaryForte Biosciences beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.08M$271.25M$5.52B$9.41BDividend YieldN/AN/A3.80%4.04%P/E Ratio-1.42N/A28.0419.84Price / SalesN/A430.80429.5399.59Price / CashN/A22.4435.8457.94Price / Book0.889.998.125.65Net Income-$74.75M-$110.10M$3.25B$258.00M7 Day Performance-1.96%-0.17%0.97%2.09%1 Month Performance-6.94%15.77%7.36%11.13%1 Year Performance706.45%20.13%31.31%18.40% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group0.7891 of 5 stars$12.50flatN/A+756.2%$20.08MN/A-1.42190FBRXForte Biosciences3.3927 of 5 stars$12.48-1.3%$61.00+388.8%+42,831.0%$83.28MN/A-0.775Gap DownENTXEntera Bio2.9448 of 5 stars$1.78-2.7%$10.00+461.8%+7.9%$83.18M$180K-6.8520TCRXTScan Therapeutics3.5939 of 5 stars$1.70+17.2%$7.80+358.8%-74.3%$82.06M$2.82M-1.56100Gap UpIGMSIGM Biosciences4.6078 of 5 stars$1.33-1.5%$5.50+313.5%-89.3%$80.70M$2.68M-0.41190Positive NewsVRCAVerrica Pharmaceuticals4.4022 of 5 stars$0.86+3.8%$8.00+828.2%-89.2%$76.77M$7.57M-0.7240CABACabaletta Bio2.833 of 5 stars$1.51+1.3%$14.43+855.5%-77.8%$75.61MN/A-0.5950EPIXESSA Pharma1.0211 of 5 stars$1.71+0.6%$2.00+17.0%-67.2%$75.46MN/A-2.7150ZURAZura Bio3.0461 of 5 stars$1.20+9.1%$14.33+1,094.4%-44.0%$75.21MN/A-1.713News CoverageGap UpIPAImmunoPrecise Antibodies3.0443 of 5 stars$1.76+8.0%$4.00+127.3%+93.3%$74.60M$18.16M-1.5280Gap UpQNCXQuince Therapeutics3.1351 of 5 stars$1.61-1.2%$8.00+396.9%+140.1%$74.11MN/A-1.1660News CoverageAnalyst Forecast Related Companies and Tools Related Companies FBRX Alternatives ENTX Alternatives TCRX Alternatives IGMS Alternatives VRCA Alternatives CABA Alternatives EPIX Alternatives ZURA Alternatives IPA Alternatives QNCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.